Evidence map›Paper›PMID 25715974›Full record

ArticleDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen2015

[Salvage surgery in esophageal cancer : Feasibility in patients after definitive radiochemotherapy (> 50 Gy)].

T Schmidt, L Sisic, F Sterzing, G-M Haag, R Kunzmann, L Grenacher, W Weichert, D Jäger, M W Büchler, K Ott

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

T SchmidtDepartment of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Deutschland.
L SisicDepartment of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Deutschland.
F SterzingDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Deutschland.
G-M HaagDepartment of Medical Oncology, National Center of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Deutschland.
R KunzmannDepartment of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Deutschland.
L GrenacherDepartment of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Deutschland.
W WeichertDepartment of Pathology, University of Heidelberg, Heidelberg, Deutschland.
D JägerDepartment of Medical Oncology, National Center of Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Deutschland.
M W BüchlerDepartment of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Deutschland.
K OttDepartment of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Deutschland. katja.ott@ro-med.de.
Heidelberg University · DEUniversity Hospital Heidelberg · DENational Center for Tumor Diseases · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSalvage surgery as an additional therapy option is currently discussed for an increasing number of patients with esophageal cancer after definitive radio(chemo)therapy after tumor progression, recurrence or on explicit request of the patient.

objectivesThe objective of this study was an analysis of the surgical option of salvage esophagectomy after definitive radiation in patients with esophageal cancer. Additionally the current literature on this topic was evaluated. MATERIAL AND

methodsA total of 92 patients with esophageal cancer from a prospective database were included in this study who underwent esophagectomy either after neoadjuvant radio(chemo)therapy (< 50 Gy) or definitive radio(chemo)therapy (> 50 Gy) between 2002 and 2012. The analysis was performed retrospectively.

resultsThe median survival of the two groups of patients was not significantly different after initial diagnosis with 24.2 months (95 % CI 0.0-51.93) for patients undergoing definitive radio(chemo)therapy and 30.7 months (95 % CI 9.3-52.2) for patients after neoadjuvant therapy (p = 0.96). Both patient groups showed no differences in pretherapeutic characteristics and response to radio(chemo)therapy. Postoperative complications and perioperative mortality were not different. DISCUSSION: Salvage esophagectomy is now an additional treatment option after definitive radio(chemo)therapy in patients with esophageal cancer. In preselected patients with tumor recurrence, progression or with a strong wish for surgical therapy, salvage surgery should be discussed in interdisciplinary tumor boards after exclusion of distant metastases.

Indexed as

ChemoradiotherapyDisease ProgressionAdenocarcinomaAdultAgedCarcinoma, Squamous CellChemoradiotherapy, AdjuvantCombined Modality TherapyCooperative BehaviorEsophageal NeoplasmsEsophagectomyFeasibility StudiesFemaleGermanyHospital MortalityHumansDefinitive radiochemotherapyEsophageal cancerNeoadjuvant radiochemotherapyPrognosisSalvage surgery

Identifiers

PMID25715974
OpenAlexW192335542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.